Charles Schwab’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-436,072
| Closed | -$40.5M | – | 3662 |
|
|
2021
Q4 | $40.5M | Buy |
436,072
+10,095
| +2% | +$665K | 0.01% | 1051 |
|
|
2021
Q3 | $25.4M | Buy |
425,977
+5,661
| +1% | +$334K | 0.01% | 1373 |
|
|
2021
Q2 | $28.7M | Buy |
420,316
+13,361
| +3% | +$871K | 0.01% | 1285 |
|
|
2021
Q1 | $28.2M | Buy |
406,955
+23,030
| +6% | +$1.77M | 0.01% | 1233 |
|
|
2020
Q4 | $29.5M | Buy |
383,925
+6,768
| +2% | +$507K | 0.01% | 1121 |
|
|
2020
Q3 | $28.2M | Buy |
377,157
+4,289
| +1% | +$286K | 0.01% | 981 |
|
|
2020
Q2 | $23.5M | Buy |
372,868
+55,186
| +17% | +$3.04M | 0.01% | 1060 |
|
|
2020
Q1 | $13.3M | Sell |
317,682
-35,062
| -10% | -$1.61M | 0.01% | 1275 |
|
|
2019
Q4 | $16M | Buy |
352,744
+766
| +0.2% | +$36.2K | 0.01% | 1367 |
|
|
2019
Q3 | $16.1M | Buy |
351,978
+16,733
| +5% | +$941K | 0.01% | 1288 |
|
|
2019
Q2 | $19.7M | Buy |
335,245
+50,778
| +18% | +$2.62M | 0.01% | 1149 |
|
|
2019
Q1 | $12.8M | Buy |
284,467
+13,505
| +5% | +$619K | 0.01% | 1438 |
|
|
2018
Q4 | $10.6M | Sell |
270,962
-1,753
| -0.6% | -$68.8K | 0.01% | 1426 |
|
|
2018
Q3 | $12.6M | Buy |
272,715
+16,065
| +6% | +$651K | 0.01% | 1479 |
|
|
2018
Q2 | $11.2M | Buy |
256,650
+38,740
| +18% | +$1.66M | 0.01% | 1520 |
|
|
2018
Q1 | $8.61M | Buy |
217,910
+8,825
| +4% | +$343K | 0.01% | 1605 |
|
|
2017
Q4 | $7.1M | Buy |
209,085
+29,732
| +17% | +$847K | 0.01% | 1710 |
|
|
2017
Q3 | $4.57M | Buy |
179,353
+47,888
| +36% | +$1.1M | ﹤0.01% | 1927 |
|
|
2017
Q2 | $2.22M | Buy |
131,465
+23,569
| +22% | +$323K | ﹤0.01% | 2189 |
|
|
2017
Q1 | $1.58M | Buy |
107,896
+21,585
| +25% | +$320K | ﹤0.01% | 2278 |
|
|
2016
Q4 | $1.23M | Buy |
86,311
+1,223
| +1% | +$18.9K | ﹤0.01% | 2364 |
|
|
2016
Q3 | $1.49M | Sell |
85,088
-7,675
| -8% | -$127K | ﹤0.01% | 2270 |
|
|
2016
Q2 | $1.59M | Buy |
92,763
+17,133
| +23% | +$306K | ﹤0.01% | 2164 |
|
|
2016
Q1 | $1.49M | Buy |
75,630
+1,504
| +2% | +$24.1K | ﹤0.01% | 2187 |
|
|
2015
Q4 | $1.41M | Buy |
74,126
+1,919
| +3% | +$39.1K | ﹤0.01% | 2238 |
|
|
2015
Q3 | $1.38M | Buy |
72,207
+888
| +1% | +$30.2K | ﹤0.01% | 2258 |
|
|
2015
Q2 | $3.31M | Buy |
71,319
+2,125
| +3% | +$92.2K | ﹤0.01% | 1811 |
|
|
2015
Q1 | $3.02M | Buy |
69,194
+7,546
| +12% | +$351K | ﹤0.01% | 1830 |
|
|
2014
Q4 | $2.14M | Buy |
61,648
+7,717
| +14% | +$313K | ﹤0.01% | 1972 |
|
|
2014
Q3 | $2.26M | Sell |
53,931
-41,340
| -43% | -$1.85M | ﹤0.01% | 1901 |
|
|
2014
Q2 | $5.58M | Buy |
95,271
+37,114
| +64% | +$2.34M | 0.01% | 1306 |
|
|
2014
Q1 | $3.66M | Buy |
58,157
+4,638
| +9% | +$308K | 0.01% | 1577 |
|
|
2013
Q4 | $3.13M | Buy |
53,519
+1,123
| +2% | +$58.7K | 0.01% | 1619 |
|
|
2013
Q3 | $2.68M | Buy |
52,396
+2,038
| +4% | +$137K | 0.01% | 1666 |
|
|
2013
Q2 | $3.8M | Buy |
+50,358
| New | +$4.11M | 0.01% | 1283 |
|
Charles Schwab's ARNA Position: Q1 2022 in Review
Charles Schwab sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 436,072 shares — an estimated $40.5M sold.
Charles Schwab first reported a position in ARNA in Q2 2013 and held it in 35 quarters. The position peaked at $40.5M in Q4 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Charles Schwab reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Charles Schwab sold 436,072 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $40.5M.
- Charles Schwab first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 35 quarters.
- Charles Schwab's Arena Pharmaceuticals Inc position peaked at $40.5M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Charles Schwab's 13F filing for Q1 2022, filed 13 May 2022.